FDA Updates Approved REMS
FDA gives an update on currently approved Risk Evaluation and Mitigation Strategies.
FDA has updated its approved Risk Evaluation and Mitigation Strategies (REMS). FDA requires REMS from manufacturers to ensure that the potential risks posed by drug products are outweighed by the benefits to patient health.
Products affected by the updates to the approved REMS include:
- Xeljianz (tofacitinib) tablets
- Buprenorphine Transmucosal Products for Opioid Dependence (BTOD)
- Extended-Release and Long-Acting Opioid Analgesics REMS
- Mycophenolate REMS
- Rosiglitazone REMS
- Transmucosal Immediate-Release Fentanyl (TIRF) Products
More information can be found at FDA.gov.
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
AES Clean Technology Launches Next-Generation OSM Utility Solution for Cleanrooms at INTERPHEX 2025
April 2nd 2025Officially launched at INTERPHEX 2025, the Omni ASCENT is a next-generation off-site manufactured vertical utility solution that offers optimized cleanroom flexibility and efficiency.
